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Theadipocyte-derivedcytokineleptinwasimplicatedtolinkinﬂammationandmetabolicalterations.Weinvestigatedthepotential
role of leptin components in critically ill patients, because systemic inﬂammation, insulin resistance, and hyperglycemia are
common features of critical illness. Upon admission to Medical Intensive Care Unit (ICU), free leptin and soluble leptin-receptor
serum concentrations were determined in 137 critically ill patients (95 with sepsis, 42 without sepsis) and 26 healthy controls.
Serum leptin or leptin-receptor did not diﬀer between patients or controls and were independent of sepsis. However, serum leptin
was closely associated with obesity and diabetes and clearly correlated with markers of metabolism and liver function. Leptin-
receptor was an unfavourable prognostic indicator, associated with mortality during three years follow-up. Our study indicates a
functional role of leptin in the pathogenesis of severe illness and emphasizes the impact of complex metabolic alterations on the
clinical outcome of critically ill patients.
1.Introduction
Hyperglycemia, glucose intolerance, and insulin resistance
are common features of critically ill patients, especially
in patients with sepsis or septic shock, even in those
without preexisting diabetes mellitus [1–3]. In patients with
obesity, metabolic syndrome, and type 2 diabetes, several
adipocytokines have been identiﬁed that mediate agonistic
and antagonistic eﬀects on insulin resistance [4, 5]. A link
between adipocytokines, inﬂammation, and systemic insulin
resistance has been established in obese and diabetic patients
[5]. In critically ill patients, little is known about the actions
of the diﬀerent adipokines, especially about their potential
impact on insulin resistance.
Since its identiﬁcation in 1994 leptin, a 16-kilodalton
hormone, has been investigated for its role in signalling food
intake,glucosehomeostasis,andenergyexpenditurethrough
hypothalamic pathways [6–8]. Circulating leptin levels
directly reﬂect adipose tissue mass and recent nutritional
status in noncritically ill individuals [9]. The mechanisms
of leptin expression are unclear, possibly insulin-stimulated
glucose metabolism and peroxysome proliferator-activated
receptor gamma (PPARγ) are involved in adipocyte leptin
induction [10, 11]. Leptin exerts its various actions on
glucose metabolism and energy expenditure via binding to
the leptin-receptor in the brain and peripheral tissues as
pancreas, liver, adipose tissue, and in the immune system
[12]. In clinical settings, free-circulating leptin as well as
solubleleptin-receptorsthatformcomplexeswithcirculating
leptin are used to understand the pathogenetic role of
leptin in regulating the inﬂammatory-metabolic response
[13]. Various animal and human studies have shown that
administration of endotoxin, TNFα, and other cytokines
as inducers of severe systemic inﬂammation result in a
signiﬁcant elevation of serum leptin concentrations [14, 15].
Our study investigated serum leptin and leptin-receptor
serumconcentrationsinalargecohortofcriticallyillpatients
(septic and nonseptic patients) from a medical ICU in order2 Mediators of Inﬂammation
Table 1: Characteristics of the study population.
Parameter All ICU patients Sepsis Nonsepsis
Number 137 95 42
Sex (number male/number female) 85/52 59/36 26/16
Sex (% male/female) 62/38 62/38 62/38
Age median (years) (range) 63 (18–81) 64 (20–81) 60 (18–79)
BMI median (kg/m2) (range) 25.4 (15.3–59.5) 25.65 (15.3–59.5) 24.9 (17.5–37.4)
Days at ICU median (range) 8 (1–137) 10 (1–137) 6 (1–45)
Days in hospital median (range) 25 (2–151) 30 (2–151) 14 (2–85)
Death at ICU n (%) 41 (29.9) 30 (31.6) 11 (26.2)
Death during follow-up n (%) 71 (51.8) 49 (51.6) 22 (52.4)
C-reactive protein median (mg/dL) (range) 112 (5–230) 167 (5–230) 14.5 (5–164)
Procalcitonin median (μg/L) (range) 0.9 (0.1–207.5) 2.2 (0.1–207.5) 0.2 (0.1–36.5)
IL-6 median (ng/L) (range) 110 (2–1000) 170 (7.7–1000) 40.5 (2–1000)
IL-10 median (ng/L) (range) 16 (5–1500) 20 (5–1500) 5.9 (5–750)
Protein median (g/L) (range) 52.5 (21–77) 52 (21–77) 55.5 (31–73)
Prothrombin time median (%) (range) 73 (11–100) 75 (11–100) 69 (13–100)
Creatinine median (mg/dL) (range) 1.6 (0.1–13.1) 1.9 (0.1–10.7) 1.2 (0.3–13.1)
Cystatin C median (mg/L) (range) 1.76 (0.41–7.30) 1.89 (0.41–6.33) 1.34 (0.41–7.30)
Glucose median (mg/dL) (range) 134 (47–663) 126 (47–299) 155 (65–663)
Insulin median (mU/L) (range) 9.8 (0.2–1000) 7.7 (0.2–438.0) 25.0 (0.2–1000)
C-peptide median (nmol/L) (range) 1.66 (0–13.0) 1.56 (0–13.0) 2.01 (0–11.6)
APACHE II score median (range) 14 (0–31) 14 (0–31) 15 (0–28)
SAPS-2 score median (range) 43 (0–80) 43 (0–79) 41.5 (13–80)
BMI: body mass index; IL: interleukin; ICU: intensive care unit; APACHE: Acute Physiology and Chronic Health Evaluation.
to understand the potential involvement of leptin and leptin-
receptor in the pathogenesis of insulin resistance in critical
illness, its regulation in severe systemic inﬂammation, and
its potential clinical use as a biomarker in ICU patients.
2. Patientsand Methods
2.1. Study Design and Patient Characteristics. The study was
approved by the local ethics committee. Written informed
consent was obtained from the patient, his or her spouse, or
theappointedlegalguardian.Atotalof137patients(85male,
52 female with a median age of 63 years; range 18–81 years)
was studied (Table 1). Patients were included consecutively
upon admission to the ICU, if they were admitted to the
MedicalICUoftheUniversityHospitalAachenduetocritical
illness. Patients were not included in this study, if they were
expected to have a short-term (<72 hours) intensive care
treatment due to postinterventional observation or acute
intoxication. Patient data, clinical information, and blood
samples were collected prospectively.
The control group consisted of 26 healthy nondiabetic
blood donors (17 male, 9 female, with a median age of
56 years; range 24–66 years) with normal values for blood
counts, C-reactive protein, and liver enzymes.
2.2. Characteristics of Sepsis and Nonsepsis Patients. Among
the137criticallyillpatientsenrolledinthisstudy,95patients
conformed to the criteria of bacterial sepsis, according to the
criteria of the American College of Chest Physicians & the
Society of Critical Care Medicine Consensus Conference
Committee for severe sepsis and septic shock [16]. In
the majority of sepsis patients, the identiﬁed origin of
infection was pneumonia (n = 54). Non-sepsis patients
did not diﬀer in age or sex from sepsis patients and were
admitted to the ICU due to cardiopulmonary disorders
(myocardial infarction, pulmonary embolism, and cardiac
pulmonary edema; n = 17), decompensated liver cirrhosis
(n = 14), or other critical conditions (n = 11). In sepsis
patients,signiﬁcantlyhigherlevelsoflaboratoryindicatorsof
inﬂammation (i.e., C-reactive protein, procalcitonin, white
blood cell count) were found than in non-sepsis patients
(Table 1, and data not shown). Nevertheless, both groups
did not diﬀer in APACHE II score, vasopressor demand, or
laboratory parameters indicating liver or renal dysfunction
(data not shown). Among all critical care patients, 29.9%
died at the ICU and 51.8% of the total initial cohort died
during the overall follow-up of 900 days (Table 1). In sepsis
and non-sepsis patients, no signiﬁcant diﬀerences in rates of
death and survival were observed (data not shown).
2.3. Comparative Variables. The patients in the sepsis and
non-sepsis groups were compared by age, sex, body mass
index (BMI), preexisting diabetes mellitus, and severity of
disease using the APACHE II score at admittance. Intensive
care treatment like volume therapy, vasopressor infusions,
demand of ventilation and ventilation hours, antibiotic and
antimycotic therapy, renal replacement therapy, and nutri-
tion were recorded, alongside a large number of laboratoryMediators of Inﬂammation 3
parameters that were routinely assessed during intensive care
treatment.
2.4. Quantiﬁcation of Human Leptin and Leptin-Receptor.
Human leptin serum concentrations were determined
with a commercial ELISA (Cat. No. RD191001100, Bio
Vendor). Intraassay (interassay) coeﬃcient of variation
(CV) ranged from 4.2% to 7.6% (n = 8) (4.4%–6.7%
(n = 6)). Human leptin-receptor concentrations in serum
were determined using a commercially available ELISA (Cat.
No. RD194002100, Bio Vendor, Candler, NC). Intraassay
(interassay) coeﬃcient of variation (CV) ranged from 7.1%
to 7.3% (n = 8) (6.2%–9.8% (n = 6)).
2.5. Statistical Analysis. Due to the skewed distribution of
most of the parameters, data are given as median, minimum,
maximum, 95% conﬁdence interval. Diﬀerences between
two groups are assessed by Mann-Whitney-U-test and mul-
tiple comparisons between more than two groups have been
conducted by Kruskal-Wallis-ANOVA and Mann-Whitney-
U-test for post hoc analysis. Box plot graphics illustrate
comparisons between subgroups. They display a statistical
summary of the median, quartiles, range, and extreme
values. The whiskers extend from the minimum to the
maximum value excluding outside and far out values which
are displayed as separate points. An outside value (indicated
by an open circle) is deﬁned as a value that is smaller than
the lower quartile minus 1.5-times interquartile range, or
largerthantheupperquartileplus1.5-timestheinterquartile
range. A far out value is deﬁned as a value that is smaller
than the lower quartile minus three times interquartile
range, or larger than the upper quartile plus three times
the interquartile range. All values, including “outliers”, have
been included for statistical analyses. Correlations between
variables have been analysed using the Spearman correlation
tests, where values of P<. 05 were considered statistically
signiﬁcant. The prognostic value of the variables was tested
by univariate and multivariate analysis in the Cox regression
model. Kaplan Meier curves were plotted to display the
impact on survival. All statistical analyses were performed
with SPSS version 12.0 (SPSS, Chicago, IL, USA).
3. Results
3.1. Leptin and Leptin-Receptor Do Not Diﬀer in Patients with
Critical Illness from Healthy Controls. I th a db e e nr e p o r t e d
that circulating leptin levels were low in critically ill patients
upon admission to the ICU, possibly due to an acute stress
response, with lowest levels in patients with sepsis [17]. We
therefore tested free leptin and soluble leptin-receptor serum
concentrationsin137criticallyillpatientsuponadmissionto
ourMedicalICU.Surprisingly,wedidnotobservesigniﬁcant
diﬀerences in ICU patients as compared to healthy controls
(Figure 1).Moreover,whenwecomparedpatientswithsepsis
(n = 95) and patients without sepsis (n = 42), no signiﬁcant
diﬀerence for either leptin or leptin-receptor concentrations
could be detected (Figures 1(b) and 1(d)). Additionally,
we performed subgroup analyses comparing patients with
Table 2: Correlation analysis.
Leptin Leptin-receptor
rPr P
Inﬂammation
Procalcitonin −0.179 .043 0.252 .004
Interleukin-10 −0.190 .049 — n.s.
Liver synthesis capacity
Protein concentration 0.342 <.001 — n.s.
Albumin concentration 0.295 .001 — n.s.
Pseudocholinesterase 0.281 .001 −0.217 .012
Prothrombin time (%) 0.266 .002 — n.s.
Antithrombin III 0.234 .012 −0.22 .017
Cholestasis
γGT — n.s. 0.204 .017
AP — n.s. 0.345 <.001
Bilirubin (total) — n.s. 0.298 <.001
Bilirubin (conjugated) — n.s. 0.373 <.001
Glucose metabolism
Insulin 0.430 <.001 −0.294 .001
C-peptide 0.285 .001 — n.s.
Lipid metabolism
Cholesterol 0.216 .013 — n.s.
HDL cholesterol 0.269 .003 — n.s.
LDL cholesterol 0.270 .003 — n.s.
Adipocytokines
Adiponectin −0.223 .015 0.548 <.001
Leptin — — −0.587 <.001
γGT:gamma-glutamyltranspeptidase;AP:alkalinephosphatase;HDL:high-
density lipoprotein; LDL: low-density lipoprotein.
sepsis of pulmonary origin to those with abdominal or other
septic focuses. However, leptin and leptin-receptor serum
concentrations did not diﬀer between these subgroups (data
not shown).
3.2. Leptin and Leptin-Receptor Are Associated with Obesity
and Diabetes in Critically Ill Patients. Leptin is a cytokine
mainly derived from adipose tissue and its concentrations
directly reﬂect adipose tissue mass and the current nutri-
tionalstatusinnoncriticallyillindividuals[4].Consequently,
we observed a close correlation between the patients’ body-
mass indices (BMI) and their leptin serum concentrations
(r = 0.478, P<. 001, Spearman rank correlation test;
Figure 2(a)). By grouping the patient cohort to diﬀerent
BMI classes (<20, 20–25, 25–30, 30–35, >35), a clear
increase in serum leptin with the BMI can be demonstrated
(Figure 2(b)). In line, an inverse association between BMI
and the circulating leptin-receptor could be revealed, with
lowest leptin-receptor concentrations in obese patients with
aB M I>35kg/m2 (Figures 2(c) and 2(d)).
Patients with a preexisting diabetes (n = 46) had signi-
ﬁcantly higher serum leptin levels (median 8.8ng/mL) than
patients without diabetes (n = 91, median leptin 4.9ng/mL,
P = .013; Figure 2(e)). However, leptin-receptor serum4 Mediators of Inﬂammation
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Figure 1: Serum leptin and leptin-receptor concentrations in critically ill patients. (a) Serum leptin levels are not diﬀerent in critically ill
patients (n = 137, median 5.5ng/mL, range 0.4–49.6) as compared to healthy controls (n = 26, median 6.6ng/mL, range 0.7–38.6). (b) No
signiﬁcant diﬀerences are detected between ICU patients with sepsis (n = 95, median 5.5ng/mL, range 0.4–49.6) and nonseptic etiology
(n = 42, range 5.4ng/mL, range 0.4–45.1) of critical illness. (c) Leptin-receptor serum concentrations do not diﬀer between critically ill
patients (median 31.5ng/mL, range 5.7–126.9) and healthy controls (median 23.9ng/mL, range 13.1–46.4). (d) No diﬀerence in serum
leptin-receptor concentrations can be observed between patients with (median 31.8ng/mL, range 5.7–126.9) or without sepsis (median
29.0ng/mL, range 7.4–124.7) at admission to the ICU. Box plot are displayed, where the bold line indicates the median per group, the box
represents 50% of the values, and horizontal lines show minimum and maximum values of the calculated nonoutlier values; asterixes and
open circles indicate outlier values.
concentrations did not diﬀer in critically ill patients with or
without diabetes (Figure 2(f)).
3.3.LeptinIsCorrelatedtoProcalcitoninandLiverDysfunction
in Critical Illness. Leptin has been functionally linked to
inﬂammatory proteins as it may directly interact with C-
reactive protein [18]. We observed an inverse correlation
between leptin and procalcitonin, but not to C-reactive
protein or interleukin-6 (Table 2). With respect to organ
dysfunction in the critically ill patients, we could not detect
a signiﬁcant correlation between leptin and renal function
(e.g., glomerular ﬁltration rate, cystatin C, creatinine; data
not shown). However, the hepatic biosynthetic capacity
was closely associated with serum leptin concentrations,Mediators of Inﬂammation 5
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Figure 2: Association of serum leptin and leptin-receptor with obesity and diabetes in critically ill patients. (a) Serum leptin concentrations
in ICU patients are correlated with the body-mass index (BMI). Spearman rank correlation test, correlation coeﬃcient r,a n dP-values are
given. (b) Among critically ill patients, serum leptin levels are signiﬁcantly associated with the patient’s BMI. Box-plot graphics are displayed
for diﬀerent classes of BMI; Kruskal-Wallis-test is used to assess signiﬁcance of the diﬀerences. (c, d) In line, an inverse association between
patient’s BMI or obesity and serum leptin-receptor levels can be detected. (e) Serum leptin is signiﬁcantly elevated in critically ill patients
with preexisting diabetes in comparison to patients without diabetes. (f) Serum leptin-receptor concentrations do not diﬀer in critically ill
patients with or without diabetes. P-values (U-test) are given in the ﬁgure. Box plot are displayed, where the bold line indicates the median
per group, the box represents 50% of the values, and horizontal lines show minimum and maximum values of the calculated nonoutlier
values; asterixes and open circles indicate outlier values.6 Mediators of Inﬂammation
as evidenced by signiﬁcant correlations to serum protein,
albumin, prothrombin time, antithrombin III, and pseudo-
cholinesterase activity (Table 2).
3.4. Leptin Is Associated with Glucose and Lipid Metabolism.
Several observations in mouse models suggested that the
actions of leptin on glucose homeostasis are independent of
itseﬀectsonfoodintake,butassociatedwithproperfunction
of hypothalamic leptin-receptors [19, 20]. We observed a
close correlation of insulin and C-peptide with leptin and an
inverse correlation with leptin-receptor (Table 2). Further-
more,markersoflipidmetabolism,forexample,totalcholes-
terol, HDL cholesterol, and LDL cholesterol were closely
associated with leptin serum concentrations (Table 2).
3.5. Leptin-Receptor Is Not Linked to Metabolic Parameters,
but to Procalcitonin and Parameters Reﬂecting Cholestasis.
In contrast to leptin, a correlation between serum leptin-
receptor concentrations and metabolic parameters could not
be found (Table 2). An association between leptin-receptor
and procalcitonin as well as insulin could be observed,
but not with other inﬂammatory or metabolic parameters
(Table 2, and data not shown). Interestingly, leptin-receptor
showedsigniﬁcantcorrelationstovariousparametersreﬂect-
ing cholestasis such as bilirubin, conjugated bilirubin,
gamma-glutamyltranspeptidase, and alkaline phosphatase
activity (Table 2). This might indicate that biliary excretion
could be possibly involved in leptin-receptor clearance.
3.6. High Leptin-Receptor Levels Indicate Unfavourable Prog-
nosis in Critically Ill Patients. Cox regression analyses and
Kaplan-Meier curves were used to assess the impact of leptin
and leptin-receptor on ICU and overall survival during
a nearly three-year follow-up among critically ill patients.
No signiﬁcant association between leptin and the ICU- or
overall-survival of the patients could be identiﬁed using
uni- and multivariate Cox regression analysis (data not
shown). Remarkably, leptin-receptor serum concentrations
upon admission to the Medical ICU were an unfavourable
indicator of ICU survival (P = .047) as well as of overall
survival (P = .034, Cox regression analysis). Using a cut-
oﬀ value for leptin-receptor of 32ng/mL, Kaplan-Meier
curves were plotted to display mortality (log rank 6.77;
Figure 3(a)). In line, surviving patients had signiﬁcantly
lower leptin-receptor concentrations (median 26.8ng/mL)
than nonsurvivors (median 34.5ng/mL, P = .037, U-test;
Figure 3(b)).
4. Discussion
Hyperglycemia and insulin resistance are common in criti-
cally ill patients and have been identiﬁed as adverse prognos-
tic predictors in ICU patients. In obesity and type 2 diabetes,
adipocytokines are critical mediators linking chronic inﬂam-
matoryconditionstosystemicinsulinresistance[5].Therole
of adipocytokines in sepsis and nonseptic ICU patients is
currently unclear. The best studied adipocytokine in critical
illness at present is resistin, which was suggested to serve as
an acute-phase component as it is strongly upregulated in
patients with severe sepsis and septic shock [21, 22]. Very
littleisknownaboutthepotentialroleofleptininthisclinical
condition.
In a recently published study, it has been reported
that serum leptin concentrations are low in all critically ill
patients on admission to the ICU, with lowest levels in sepsis
patients [17]. As a possible mechanism, reduced synthesis
or increased removal either by extravasation due to capillary
leakage in sepsis or increased metabolic clearance has been
speculated [17]. In this study by Langouche et al., the SOFA
score on admission was statistically signiﬁcantly higher in
sepsis patients as compared to nonseptic patients. Moreover,
a prior study demonstrated decreased plasma leptin levels
due to trauma which were explained to be partly related
to the initial fasting conditions, because refeeding elevated
serum leptin concentrations to normal levels [23].
In our study, the leptin and leptin-receptor concentra-
tions did not diﬀer in patients with critical illness from
healthy controls. Subgroup analysis revealed no signiﬁcant
diﬀerenceinsepsisandnon-sepsispatientsaswell(Figure 1).
This diﬀerence might very likely be related to our cohorts of
septic and nonseptic patients, which were very homogenous
in terms of severity of illness as reﬂected by APACHE II and
SOFA score. Moreover, our study population had a slightly
higher median BMI and therefore possibly a better nutri-
tional status in the subgroups of patients with and without
proven sepsis. However, in contrast to prior observations,
our data indicate that circulating leptin and leptin-receptor
levels are not severely dysregulated in critically ill patients at
the point of admission to the ICU.
Leptin has various peripheral and central targets, includ-
ing cells of the brain, pancreas, liver, adipose tissue, and
immune system [12]. In animal models, deletion of the
cerebral leptin-receptor leads to obesity and elevated plasma
levels of leptin, glucose, and insulin [24]. Leptin deﬁciency
in humans either due to an absolute shortage of leptin or
due to leptin-receptor mutations causes severe early onset
obesity, hyperphagia, hyperinsulinemia, hypogonadism, and
impaired T cell function [25]. In individuals with leptin-
receptor defects, the features of leptin deﬁciency appear
ameliorated, which might give a hint for the existence of
alternative, leptin-receptor independent, leptin signalling
pathways [26]. In line with the current view of leptin as
being a cytokine, mainly derived from adipose tissue and
reﬂects adipose tissue mass, we found a close association
to the patients’ BMI (Figures 2(a) and 2(b)). Accordingly,
an inverse association could be observed for the circulating
leptin-receptor (Figures 2(c) and 2(d)), which is expressed
by various tissues and serves as a binding partner for leptin
in the circulation [24].
The regulation of glucose metabolism by leptin is
likely independent of its eﬀect on food intake and energy
expenditure. Hypothalamic expression of leptin-receptor in
animal model resulted in modest reduction of food intake
and body fat mass, but in normalized blood glucose and
insulin levels [19]. The present data suggest the existence of
two leptin signalling pathways: the leptin-receptor mediated
JAK-STAT (Janus kinase signal transducers and activatorsMediators of Inﬂammation 7
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Figure 3: Prognostic relevance of serum leptin-receptor in critically ill patients. (a) Kaplan-Meier survival curves of ICU patients (n = 137)
are displayed, showing that patients with high leptin-receptor levels (>32ng/m/L, black) have an increased mortality as compared to patients
withlowserumleptin-receptor(≤32ng/mL,grey).P-valuefromCoxregressionanalysisis .034.(b)Patientsthatdieduringfollow-upperiod
treatment (n = 71, 51.8%) have signiﬁcantly (P = .037) higher serum leptin-receptor levels on admittance to ICU than survivors (n = 66,
48.2%). Box plot are displayed, where the dotted line indicates the median per group, the box represents 50% of the values, and horizontal
lines show minimum and maximum values of the calculated nonoutlier values; asterixes and open circles indicate outlier values.
of transcription) signalling for regulation of food intake
and body weight, and PI3K (phosphoinositide-3 kinase)
pathway for regulation of glucose metabolism [19, 20, 27].
These experimental ﬁndings might very well explain why we
did not only observe a strong association between patients’
BMI and leptin, but also between glucose metabolism (e.g.,
insulin secretion) and serum leptin levels in critically ill
patients.
The possible interaction between leptin and systemic
inﬂammation is a matter of ongoing debate. It has been
reported that human C-reactive protein (CRP) inhibits the
binding of leptin to its speciﬁc receptor and blocks signal
transduction in cultured cells and mouse models; thus, it
might attenuate the physiological function of leptin and
contribute to the concept of “leptin resistance” [18]. In
our study, we could demonstrate an inverse correlation
between leptin and procalcitonin and a direct correlation
between leptin-receptor and procalcitonin, but not with
“classical” markers of inﬂammation as C-reactive protein or
interleukin-6. Possibly, acute bacterial inﬂammation, as dis-
played by procalcitonin, in critically ill patients contributes
to the state of “leptin resistance,” yet the clinical impact of
“leptin resistance” in critical illness is still unsettled.
Furthermore, we analyzed the association of leptin with
markers of organ function in ICU patients. Leptin did not
correlate with renal function as reﬂected by glomerular
ﬁltration rate, cystatin C, and creatinine. We observed that
the hepatic biosynthetic capacity was closely related to leptin
levels (Table 2). This ﬁnding in critically ill patients is in
contrast to reports from patients with liver cirrhosis, in
which leptin levels are rather upregulated [13, 28].
Remarkably, leptin-receptor serum concentrations upon
admission to the Medical ICU were an unfavourable indica-
tor of ICU survival (P = .047) as well as of overall survival
(P = .034) (Figures 3(a) and 3(b)). Surviving patients had
signiﬁcantly lower leptin-receptor concentrations than non-
survivors.Thisobservationwashighlyunexpected,especially
since leptin-receptor was not an obvious surrogate marker
for other alterations, for example, inﬂammation, organ
failure, in critically ill patients. The association with survival
was independent from other parameters by multivariate
regression analysis (data not shown). The exact functional
contribution of soluble leptin-receptor or free leptin in the
pathogenesis of critical illness or sepsis is currently unclear,
and additional studies in experimental models are war-
ranted. It is also important to note that future studies should
incorporate longitudinal measurements of leptin and leptin
receptor during the course of critical illness, as this might
help to clarify the potential pathogenic contributions at
diﬀerent phases of initiation and recovery from acute illness.
However, the association of leptin-receptor with survival
raises the possibility that including serum leptin-receptor8 Mediators of Inﬂammation
concentrations might improve the validity of prognostic
assessments in critically ill patients upon admission to the
ICU.
5. Conclusions
Although leptin and leptin-receptor serum concentrations
do not diﬀer in patients with critical illness or in the
subgroups of patients with and without sepsis from healthy
controls, serum leptin in critically ill patients is closely cor-
related with the patients’ BMI and metabolic alterations. The
possiblefunctionalroleofleptininthepathogenesisofsevere
illness warrants further studies. However, soluble leptin-
receptor turned out to be an independent prognostic marker
at admission to the Medical ICU, thereby emphasizing the
impact of the complex metabolic alterations on the clinical
outcome of critically ill patients.
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